Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer

Hao, Tao; Shi, Weixiang; Shen, Xianjuan; Qi, Jin; Wu, Xinhua; Wu, Yong; Tang, Yanna; Ju, Shaoqing

doi:10.1038/bjc.2014.470

Cited by 165 publications

(155 citation statements)

References 42 publications

Supporting

Mentioning

141

Contrasting

Order By: Relevance

“…In general, the levels are higher in mCRC patients than in healthy controls, as shown in Table 1 [15,20,47,58,[63][64][65][66][67][68][69][70][71][72]; and the levels have some correlation to stage as reported in a limited number of studies [15,41,68,73] in primary CRC. These findings give important biological information, and researchers suggest that cfDNA has potential as a diagnostic or screening tool; a potential that is currently being investigated by several groups.…”

Section: Methodsmentioning

confidence: 74%

“…The size of DNA fragments seems to hold important biological information. This has been explored by several groups advocating that a cfDNA integrity index should be used in clinical investigations [15,20,53]. Although the potential that lies in detection and measurement of the tumor-specific DNA has been established, the clinical value of total cfDNA quantification is still being debated.…”

Section: Methodsmentioning

confidence: 99%

“…It is therefore relevant to analyze the relation between cfDNA and CEA. As illustrated from the summary in Table 2, there is considerable variation in the measures, methods and parameter used to compare or combine the information from CEA and cfDNA analysis [15,20,32,33,39,41,[65][66][67][68][69][70][71][72][81][82][83]. The table includes studies identified by a systematic literature search of circulating DNA in CRC (all stages) as illustrated by Supplementary Figure 1.…”

Section: Methodsmentioning

confidence: 99%

“…Another stand of research explores the potential clinical value of measuring the cfDNA and the emergence of recent technologies has enabled investigation of relevant cohorts of cancer patients in clinical settings. Several studies indicate a potential prognostic, predictive and diagnostic value of measuring the cfDNA, which calls for reliable validation [14][15][16][17][18][19][20][21][22][23].…”

Section: Metastatic Colorectal Cancermentioning

confidence: 99%

See 3 more Smart Citations

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Spindler

2016

Acta Oncologica

View full text Add to dashboard Cite

Background: Circulating DNA can be used to measure the total cell-free DNA (cfDNA) and for detection and quantification of tumor-specific genetic alterations in the peripheral blood, and the broad clinical potential of circulating DNA has attracted increasing focus over the past decade. Concentrations of circulating DNA are high in metastatic colorectal cancer (CRC), and the total levels of cfDNA have been reported to hold strong prognostic value. Colorectal tumors are characterized by a high frequency of well known, clinically relevant genetic alteration, which is readily detected in the cfDNA and holds potential for tailoring of palliative therapy and for monitoring during treatment. This review aims to present the current literature which has specifically reported data on the potential utility of cfDNA and on tumor-specific mutations in metastatic colorectal cancer (mCRC). Method: Methodological, biological and clinical aspects are discussed based on the most recent development in this specific setting, and eligible studies were identified by systematic literature searched from Pubmed and EMBASE in addition to conference papers and communications. Results: The literature regarding cfDNA in CRC is broad and heterogeneous concerning aims, nomenclature, methods, cohorts and clinical endpoints and consequently difficult to include in a single systematic search. However, the available data underline a strong clinical value of measuring both total cfDNA levels and tumor-specific mutations in the plasma of patients with mCRC, pre-and during systemic therapy. Conclusion: This paper had gathered the most recent literature on several aspects of cfDNA in mCRC, including methodological, biological and clinical aspects, and discussed the large clinical potential in this specific setting, which needs to be validated in carefully designed prospective studies in statistically relevant cohorts.

show abstract

Section: Methodsmentioning

confidence: 74%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Metastatic Colorectal Cancermentioning

confidence: 99%

See 2 more Smart Citations

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Spindler

2016

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…11 High plasma DNA concentration has been correlated with tumor metastasis, 12 response to therapy, and relapse. 13 This suggests that the plasma DNA has the potential to be a tumor-specific biomarker for diagnosis, prognosis, and early detection of cancer.…”

Section: Introductionmentioning

confidence: 99%

Plasma DNA as a potential biomarker for breast cancer detection

Purnomosari¹,

Indrayani²,

Irianiwati³

et al. 2016

JMedScie

View full text Add to dashboard Cite

Breast cancer is a major malignancy among Indonesian women. It is often diagnosed in the later stages of cancer, which leads to poor prognosis and survival of the patients. This study investigated plasma DNA concentration as a potential biomarker for breast cancer. The benefit of using this detection is the cost-effectiveness and the samples can be collected from patients using non-invasive methods. Plasma samples were obtained from healthy controls (n=18) and cancer patients (n=22). Each sample was split into two equal portions for DNA isolation using two different methods for the NaI method and a commercially available kit (Qiagen/ QA) method. The DNA concentration was determined by using a GeneQuant spectrophotometer (Pharmacia). The t-test was used for statistical analysis, which was performed using the SPSS 17.0 software. Compared to the commercial method, extraction using NaI yielded higher DNA concentration, both from samples of healthy controls and cancer patients (p=0,008 and p=0.000, respectively). Furthermore, regardless of the isolation method used, the plasma DNA concentration was higher in healthy controls than in cancer cases (p=0,032 and p=0.005, for NaI and QA methods, respectively). In conclusion, isolation methods significantly affect DNA concentrations. The plasma DNA concentration of healthy controls is significantly higher than those of the cancer cases, suggesting that plasma DNA concentration might be a potential biomarker for breast cancer detection with less invasive sampling method than tissue biopsies. ABSTRAKKanker payudara adalah keganasan utama pada wanita di Indonesia. Penyakit ini seringkali terdiagnosis pada stadium lanjut sehingga mengakibatkan rendahnya keberhasilan pengobatan dan ketahanan hidup pasien yang buruk. Studi ini meneliti potensi DNA plasma sebagai penanda biologis untuk mendeteksi kanker payudara. Penggunaan DNA plasma sebagai penanda biologis dianggap menguntungkan mengingat analisisnya yang ekonomis dan menggunakan pendekatan yang tidak invasif. Sampel plasma darah diperoleh dari individu sehat (n=18) dan pasien kanker payudara (n=22) setelah mendapat persetujuan dengan menandatangani informed-consent. Setiap sampel dipisahkan menjadi 2 bagian dengan volume yang sama untuk diekstrasi menggunakan 2 metode yang berbeda yaitu metode Na-I dan kit ekstraksi komersial (Qiagen/QA). Konsentrasi DNA plasma diukur dengan spektrofotometer (Genequant, Pharmacia). Analisis statistik t-tes digunakan untuk melihat perbedaan kedua metode tesebut. Metode ekstraksi Na-I menujukkan konsentrasi DNA yang lebih tinggi dibandingkan kit komersial, baik pada individu sehat (p=0.008) 201Purnomosari et al., Plasma DNA as a potential biomarker for breast cancer detection maupun pasien kanker payudara (p=0.000). Sejalan dengan hasil di atas, konsentrasi DNA plasma pada individu sehat lebih tinggi daripada penderita kanker payudara menggunakan 2 metode yang berbeda (NaI p=0.032 dan kit komersial p=0.005). Dapat disimpulkan bahwa metode ekstraksi DNA menentukan konsentrasi DNA yang di...

show abstract

Predictive and Prognostic Markers for Cancer Medicine

Yilmaz

Yörüker

2020

Precision Medicine in Oncology

View full text Add to dashboard Cite

Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer

Cited by 165 publications

References 42 publications

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

Plasma DNA as a potential biomarker for breast cancer detection

Predictive and Prognostic Markers for Cancer Medicine

Contact Info

Product

Resources

About